Trials / Completed
CompletedNCT03767738
Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Aflibercept Injection (IAI) | IAI prepared and administered with a pre-filled syringe (PFS) |
Timeline
- Start date
- 2018-12-19
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2018-12-07
- Last updated
- 2021-09-16
- Results posted
- 2021-09-16
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03767738. Inclusion in this directory is not an endorsement.